Core Viewpoint - Lihua Microelectronics (688589.SH) announced that its share reduction plan, issued by Lihua Science and Technology, has reached its deadline as of February 12, 2026, and no shares have been sold by Lihua Science and Technology [1] Group 1 - The share reduction plan's implementation period has officially ended [1] - Lihua Science and Technology has not reduced its holdings in Lihua Microelectronics [1]

Core Viewpoint - The company, Guojizhongzhuang (601399.SH), has received a notification from Agricultural Bank of China (ABC) Sichuan and Jiangsu branches regarding their share reduction plan, indicating a potential decrease in shareholding by these banks [1] Group 1: Share Reduction Plan - ABC Sichuan and Jiangsu branches plan to reduce their holdings by a total of up to 72.13 million shares through centralized bidding, which represents no more than 1% of the company's total share capital [1] - Additionally, the banks intend to reduce their holdings by up to 144 million shares through block trading, accounting for no more than 2% of the company's total share capital [1]

格隆汇2月12日丨福达合金(603045.SH)公布，公司于近日收到公司控股股东王达武先生的《股份减持计 划告知函》，王达武先生因自身资金需求，计划自本公告披露之日起15个交易日后的3个月内，拟通过 集中竞价、大宗交易方式合计减持公司股份不超过406.34万股，即不超过公司总股本的3%；其中，采 取集中竞价交易方式减持时，在任意连续90日内，减持股份的总数不超过135.45万股（即不超过公司总 股本的1%）；采取大宗交易方式减持时，在任意连续90日内，减持股份的总数不超过270.89万股（即 不超过公司总股本的2%）。减持价格按照减持实施时的市场价格确定。 ...

Core Viewpoint - The company has successfully issued its third tranche of medium-term notes for the year 2026, indicating a strategic move to raise capital through debt instruments [1] Group 1: Bond Issuance Details - The bond is named "Shanghai International Port Group Co., Ltd. 2026 Annual Third Tranche Medium-Term Notes" [1] - The bond code is 102680513, with a maturity period of 5 years and a redemption date set for February 12, 2031 [1] - The total amount issued is 2 billion yuan, with an interest rate of 1.81% [1]

截至目前，公司已收到众恒电气支付的本次股权转让的全部价款，并且南京天石已完成办理相应的工商 变更登记手续。至此，公司不再持有南京天石股权。 2026年1月13日，公司与南京众恒电气有限公司（以下简称"众恒电气"）签订了关于转让南京天石软件 技术有限公司11.11%股权的《上海市产权交易合同》，交易价格为人民币1,748.00万元。 格隆汇2月12日丨开开实业(600272.SH)公布，公司于2025年12月5日通过上海联合产权交易所以公开挂 牌转让的方式将所持有的南京天石软件技术有限公司（以下简称"南京天石"）11.11%股权进行转让，挂 牌价格为人民币1,747.31万元，挂牌期间仅征集到一个合格意向受让方。 ...

格隆汇2月12日丨安迪苏(600299.SH)公布2025年中期权益分派实施公告，本次利润分配以方案实施前的 公司总股本3,079,779,257股为基数，每股派发现金红利0.051元(含税)，共计派发现金红利157,068,742.11 元(含税)。 本次权益分派股权登记日为：2026年2月26日，除权除息日为：2026年2月27日。 ...

格隆汇2月12日丨空港股份(600463.SH)公布，公司于2026年2月12日收到持股5%以上股东国开金融出具 的《关于股东减持权益变动跨越1%的整数倍的告知函》。获悉国开金融于2025年10月30日、2025年11 月5日、2025年11月6日、2025年11月7日、2026年2月12日，通过集中竞价方式减持其持有的公司股票共 396.03万股，占公司总股本的1.32%。本次权益变动后，公司持股5%以上股东国开金融持有公司股份数 量由30,000,000股减少至26,039,700股，占公司总股本比例由10.00%减少至8.68%，触及跨越1%的整数 倍。 ...

Core Viewpoint - The company, Yuhua Development (000514.SZ), has approved the sale of 177 residential units from the Jinyu New Metropolitan Tianchen project, aiming to enhance asset operation efficiency and structure through public market transactions [1] Group 1: Asset Sale Details - The company will sell 177 residential units with a total construction area of 19,523.79 square meters [1] - The units will be listed at a price of 12,880 yuan per square meter, with a minimum listing price of 251,466,415.20 yuan [1] - The board has authorized the management to handle the specific matters related to the listing and transfer [1] Group 2: Financial Implications - If all 177 residential units are sold at the minimum listing price, the company is expected to generate a net profit of approximately 17.78 million yuan [1]

Group 1 - The core topic of the article revolves around the investment strategies of "holding stocks during the holiday" versus "holding cash during the holiday," particularly in the context of the upcoming Chinese New Year [1] - Historical data shows that the A-share market has a significant "pre-holiday effect," with trading volumes typically decreasing before the holiday and increasing afterward, indicating a potential for market recovery post-holiday [2][17] - Recent market trends indicate a rebound in stock indices, driven by AI-related catalysts, suggesting a prelude to the holiday market performance [3][14] Group 2 - The article highlights that the cash withdrawal demand during the holiday season leads to a seasonal decline in the banking system's excess reserve ratio, impacting market liquidity [5] - The recent adjustments in the market are seen as a necessary phase for paving the way for post-holiday opportunities, with many institutions remaining optimistic about the market's performance after the holiday [15][34] - The article notes that the recent volatility in the market is influenced by external factors, including adjustments in commodity prices and the performance of major tech companies in the U.S. [8][9] Group 3 - The article discusses the recent performance of various sectors, particularly the rapid rotation among themes such as optical communication, computing power chains, and commercial aerospace, which have shown significant gains [14] - The "spring market" phenomenon has already begun, with indices like the CSI 500, 1000, and 2000 showing early upward trends since late December, indicating a bullish sentiment in the market [19][20] - The introduction of AI models like Seedance 2.0 is expected to catalyze further growth in the A-share market, particularly in the media sector, as it enhances content production efficiency [26][30] Group 4 - The article emphasizes that the upcoming macroeconomic data releases, including domestic inflation and social financing figures, are crucial for validating the improvement in the fundamental outlook [15][17] - The anticipated increase in liquidity post-holiday, combined with policy catalysts, is expected to create a favorable environment for market recovery and growth [22][31] - The article concludes that maintaining a stock position during the holiday is likely to yield higher returns, supported by historical performance data showing a positive trend in the market after the holiday [15][34]

Core Viewpoint - The approval of the abbreviated new drug application for Acetate Glatiramer Injection by the U.S. FDA marks a significant milestone for the company, enhancing its product pipeline and market presence in the U.S. [1] Group 1: Product Information - Acetate Glatiramer is an immunomodulatory drug used for treating relapsing forms of multiple sclerosis (MS) [1] - The drug mimics the structure of myelin basic protein to regulate abnormal autoimmune responses, thereby reducing attacks on the central nervous system's myelin [1] - It is effective in lowering relapse frequency and delaying disease progression, suitable for patients with clinical isolated syndrome and relapsing-remitting multiple sclerosis [1] Group 2: Market Impact - The approval will enrich the company's overseas product pipeline and broaden its pharmaceutical market in the U.S. [1] - The company plans to actively promote the sales of this drug in overseas markets, which is expected to positively impact future performance and industry standing [1]